【英硅智能首款AI药物进入III期临床研究】业界首款完成AI药物临床药效验证的候选药物Rentosertib正式启动III期临床试验，相关信息已在中国国家药品监督管理局药品审评中心平台公示，并于ClinicalTrials.gov网站登记。这是英硅智能旗下首款由自有生成式AI平台Pharma.AI驱动的候选药物，其创新靶点和新颖结构均由AI辅助发现，并具有“全球首创”潜力用于特发性肺纤维化治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.